ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla's Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX...
Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select Industry Index has dropped by 4%.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20 p.m. ET / 11:20 a.m. PT on Tuesday, May 14 in Las Vegas. Citizens JMP Life Sciences Conference: Exelixis...
EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the judge's decision, but have acquired some calls for ~1% of portfolio to benefit from a positive outcome.
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director of Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer P.J. Haley - Executive Vice President, Commercial Amy Peterson - Executive Vice President, Product Devel...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. “In the first quarter of 2024, Exelixis made important progress to advance a diverse, multi-produ...
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant, there is no denying the risk involved.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.